Vanderbilt Avenue

Celcuity Announces Pricing of Underwritten Common Stock Offering

Retrieved on: 
Donnerstag, Mai 30, 2024
Patient, Fulvestrant, CELC, Investment, Suite, Telephone, Sale, Breast cancer, Form, Prospectus, Research, Attention, Vanderbilt Avenue, SVB Securities, Richard Driehaus, State Street, Public expenditure, Clinical trial, Montgomery Street, Security (finance)

MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share.

Key Points: 
  • MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share.
  • The offering is expected to close on or about May 31, 2024, subject to satisfaction of customary closing conditions.
  • Gross proceeds to Celcuity from the offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and offering expenses.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Montag, Mai 20, 2024
Security (finance), Equity capital markets, Form S-3, Jefferies, Therapy, Telephone, TD Securities, Sale, Jefferies Group, Form, Foghorn, Prospectus, Attention, Vanderbilt Avenue, Evercore, Madison Avenue

The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions.
  • All of the shares of common stock in the offering are to be sold by Foghorn.
  • Foghorn anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commissions and estimated offering expenses) will be approximately $110 million.
  • Foghorn intends to use the net proceeds from this offering to advance its preclinical and clinical programs and for general corporate purposes.

Tilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis Rescheduling When Effective

Retrieved on: 
Freitag, Mai 17, 2024
EDGAR, ATTN:, Investment, Jefferies, Telephone, TD Securities, Sale, Jefferies Group, Form, Prospectus, Common stock, File, Vanderbilt Avenue, TLRY, TSX, Madison Avenue, Security (finance)

The timing and amount of any such sales will be determined by a variety of factors considered by the Company.

Key Points: 
  • The timing and amount of any such sales will be determined by a variety of factors considered by the Company.
  • Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices.
  • The Company does not currently intend to use the net proceeds from the ATM Program for general working capital purposes.
  • A prospectus supplement and accompanying prospectus relating to the ATM Program was filed with the SEC on May 17, 2024.

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Retrieved on: 
Donnerstag, Mai 16, 2024
ATTN:, Therapy, Telephone, Sale, MGD, Dimension, Vanderbilt Avenue, Montgomery Street, Security (finance)

The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100 million.

Key Points: 
  • The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100 million.
  • All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa.
  • The offering is expected to close on or about May 20, 2024, subject to satisfaction of customary closing conditions.
  • The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Mittwoch, Mai 15, 2024
ATTN:, Therapy, Telephone, Sale, MGD, Vanderbilt Avenue, Montgomery Street, Security (finance)

BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.

Key Points: 
  • BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.
  • All of the shares of common stock and pre-funded warrants to purchase shares of common stock in the proposed offering are to be sold by Monte Rosa.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

CompoSecure Announces Pricing of Secondary Offering of Shares of Class A Common Stock by Selling Shareholders

Retrieved on: 
Donnerstag, Mai 9, 2024
Sale, Prospectus, Offering, Roth Capital Partners, Vanderbilt Avenue, Security (finance), Form S-3, Form, Common stock, BofA Securities, Attention, Telephone, Needham & Company

In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase an additional 1,050,000 shares of Class A Common Stock.

Key Points: 
  • In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase an additional 1,050,000 shares of Class A Common Stock.
  • CompoSecure will not receive any of the proceeds from the sale of the shares by the Selling Shareholders.
  • The Offering is being made pursuant to CompoSecure’s existing resale registration statement on Form S-1, as amended by Post-Effective Amendment No.
  • Copies of the final prospectus relating to the Offering may be obtained, when available, from: by visiting the SEC’s website at www.sec.gov.

CompoSecure Announces Launch of Secondary Offering of Shares of Class A Common Stock by Selling Shareholders

Retrieved on: 
Mittwoch, Mai 8, 2024
Sale, Prospectus, Common, Offering, Vanderbilt Avenue, Security (finance), Form S-3, Form, Common stock, BofA Securities, Attention, Telephone

SOMERSET, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (“CompoSecure” or the “Company”) (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the commencement of an underwritten public offering (the “Offering”) of 7,000,000 shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), by certain shareholders of the Company (the “Selling Shareholders”).

Key Points: 
  • SOMERSET, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (“CompoSecure” or the “Company”) (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the commencement of an underwritten public offering (the “Offering”) of 7,000,000 shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), by certain shareholders of the Company (the “Selling Shareholders”).
  • In connection with the Offering, the Selling Shareholders expect to grant the underwriters a 30-day option to purchase an additional 1,050,000 shares of Class A Common Stock.
  • CompoSecure is not offering any shares of its Class A Common Stock in the Offering and will not receive any proceeds from the sale of shares of Class A Common Stock in the Offering.
  • J.P. Morgan, BofA Securities and TD Cowen are acting as joint book-running managers for the Offering.

Silvaco Announces Pricing of Initial Public Offering

Retrieved on: 
Donnerstag, Mai 9, 2024
Software, Networks, Internet, Data Management, Technology, Apps, Applications, Mobile, Wireless, Security, Sale, Prospectus, TCAD, AI, Vanderbilt Avenue, Jefferies, Research, Madison Avenue, Public expenditure, SIP, Jefferies Group, EDA, Capital Group Companies, Marketing, Rosenblatt, Attention, Telephone, Needham & Company, Security (finance)

Silvaco Group, Inc. (“Silvaco”), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and AI through software and innovation, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $19.00 per share.

Key Points: 
  • Silvaco Group, Inc. (“Silvaco”), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and AI through software and innovation, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $19.00 per share.
  • The aggregate gross proceeds to Silvaco from the offering are expected to be $114.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Silvaco.
  • In addition, Silvaco has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of Silvaco’s common stock from Silvaco at the public offering price, less underwriting discounts and commissions.
  • Needham & Company is acting as lead manager and Craig-Hallum Capital Group and Rosenblatt are acting as co-managers for the offering.

AvalonBay Communities, Inc. Prices $400 Million Senior Notes Offering

Retrieved on: 
Dienstag, Mai 7, 2024
Other Construction & Property, Residential Building & Real Estate, Construction & Property, REIT, Goldman Sachs, Sale, Investment, Kitchen Party (girl group), Brookfield Place, RBC Capital Markets, Morgan Stanley, Vanderbilt Avenue, Vesey Street, Security (finance), Barclays, TD Securities, Deutsche Bank, EDGAR, Acquisition, Database, BofA Securities, Scotiabank, BNP Paribas, Wells Fargo, Fifth Avenue, Attention, Telephone, Note

The effective interest rate of the Notes is 4.961%, including the impact of prior interest rate hedges, but excluding offering costs.

Key Points: 
  • The effective interest rate of the Notes is 4.961%, including the impact of prior interest rate hedges, but excluding offering costs.
  • Interest on the Notes will be paid semi-annually on June 1 and December 1, with the first payment to be made on December 1, 2024.
  • The Notes will mature on June 1, 2034, unless earlier redeemed.
  • Barclays, BNP Paribas, Deutsche Bank Securities, Mizuho, US Bancorp, and Ramirez & Co., Inc. are acting as co-managers of the offering.

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Mittwoch, April 24, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Varick Street, Patient, 2nd Floor, S-3, TCR, Attention, Therapy, Telephone, Needham & Company

Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.

Key Points: 
  • Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.
  • LifeSci Capital acted as lead manager, and BTIG, H.C. Wainwright & Co. and Needham & Company acted as co-managers for the offering.
  • The offering was made only by means of a preliminary prospectus supplement and accompanying filed with the SEC.
  • A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC.